THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular.

If you are in any doubt as to any aspect of this circular or as to the action to be taken, you should consult the registered dealer in securities, bank manager, solicitor, professional accountant or other professional adviser.

If you have sold or transferred all your shares in **Hangzhou Tigermed Consulting Co., Ltd**., you should at once hand this circular and the accompanying form of proxy to the purchaser or transferee, or to the bank, registered dealer in securities or other agent through whom the sale or the transfer was effected for transmission to the purchaser or transferee.

This circular appears for information purposes only and is not intended to and does not constitute, or form part of, an invitation or offer to acquire, purchase or subscribe for any securities of the Company, the Offeror or the Offeree nor is it a solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance or transfer of securities of the Company, the Offeror or the Offeree in any jurisdiction in contravention of applicable law or regulation.

This circular is not for release, publication or distribution, in whole or in part, in, into or from any jurisdiction where to do so would constitute a violation of the Applicable Laws of such jurisdiction.

HANGZHOU TIGERMED CONSULTING CO., LTD.

杭州泰格醫藥科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3347)

(1) PRIVATIZATION AND SEPARATION TRANSACTION OF FRONTAGE HOLDINGS CORPORATION; AND (2) NOTICE OF 2026 FOURTH EXTRAORDINARY GENERAL MEETING

All capitalized terms used in this circular have the meanings set out in the section headed "Definitions" of this circular. A letter from the Board is set out on pages 7 to 13 of this circular.

The EGM of the Company will be held at 10:00 a.m. on Friday, December 4, 2026 at the Conference Room, 6/F, No. 508 Lujiatian Street, Puyan Sub-District, Binjiang District, Hangzhou, the PRC. A notice of the EGM is set out on pages EGM-1 to EGM-2 of this circular.

The form of proxy for use at the EGM was published on the websites of the Stock Exchange at (www.hkexnews.hk) and the Company (www.tigermedgrp.com) on Tuesday, November 17, 2026. If you intend to appoint a proxy to attend the EGM, you are requested to complete and return the form of proxy in accordance with the instructions printed thereon as soon as practicable and in any event not later than 24 hours before the time fixed for holding the EGM or any adjournment thereof (as the case may be). Completion and return of the form of proxy will not preclude you from attending the EGM and voting in person if you so wish.

November 17, 2026

CONTENTS

Pages

Definitions 1

Letter from the Board 7

Notice of the EGM EGM-1

Unless the context otherwise requires, the following expressions in this circular shall have the following meanings:

"A Share Announcements"	the overseas regulatory announcements of the Company dated November 9, 2026 relating to the privatization and Separation Transaction of Frontage Holdings;
"A Shares"	the ordinary share(s) issued by the Company and subscribed for in RMB, which are listed on the SZSE;
"Announcement"	the announcement of the Company dated November 9, 2026 relating to the discloseable and connected transaction in relation to the privatization and separation transaction of Frontage Holdings;
"Applicable Laws"	with respect to any person, any laws, rules, regulations, guidelines, directives, treaties, judgments, decrees, orders or notices of any Authority that is applicable to such person;
"Articles of Association"	the articles of association of the Company, as amended from time to time;
"Authorit(ies)"	any relevant government, governmental, quasi-governmental, statutory, administrative or regulatory body, or court, tribunal, arbitrator or governmental agency or authority or department (including any relevant securities exchange) and whether supranational, national, regional or local;
"Board"	the board of Directors of the Company;
"Company"	Hangzhou Tigermed Consulting Co., Ltd. (杭州泰格醫藥科技股份有限公司), a company established under the laws of the People's Republic of China, the A shares of which are listed on the Shenzhen Stock Exchange (stock code: 300347) and the H shares of which are listed on the Stock Exchange (stock code: 3347);
"Company Law"	the Company Law of the People's Republic of China (《中華人民共和國公司法》);
"Conditions"	has the meaning ascribed to it in the Announcement;
"connected person(s)"	has the meaning ascribed to it under the Hong Kong Listing Rules;
"Consortium Agreement"	has the meaning ascribed to it in the Announcement;

"Consortium Members"	CRL, Hongkong Tigermed and Dr. Li, and each of CRL, Hongkong Tigermed and Dr. Li will be referred to as a "**Consortium Member**";
"CRL"	Charles River Laboratories International, Inc., a company incorporated under the laws of Delaware, the common stock of which is listed on New York Stock Exchange (ticker: CRL);
"CRO"	Contract Research Organization, an organization focused on providing research and development services to companies in the pharmaceutical and agrochemical markets;
"Director(s)"	the directors of the Company;
"Dr. Li"	Dr. Song Li, the chairman of the board of directors of the Offeree;
"Dr. Li's Trusts"	The Joint Trust of Song Li and Lei Wang f/b/o Linna Li dated December 22, 2025 (The Linna Li GST Exempt Trust), the Joint Trust of Song Li and Lei Wang f/b/o Wendy Li dated December 22, 2025 (The Wendy Li GST Exempt Trust) and the Joint Trust of Song Li and Lei Wang f/b/o Yue Monica Li dated December 22, 2025 (The Yue Monica Li GST Exempt Trust), in which Dr. Li is the grantor;
"Earnout Arrangement"	has the meaning ascribed to it in the Announcement;
"Effective Date"	the date on which the Scheme becomes effective in accordance with the Companies Act (As Revised) of the Cayman Islands and the Conditions;
"EGM"	the 2026 fourth extraordinary general meeting of the Company to be held at 10:00 a.m. on Friday, December 4, 2026 at the Conference Room, 6/F, No. 508 Lujiatian Street, Puyan Sub-District, Binjiang District, Hangzhou, the PRC;
"Frontage ACE"	Frontage ACE LLC, a limited liability company incorporated under the laws of Delaware, United States and wholly-owned by Dr. Li as at the Latest Practicable Date;
"Frontage International Limited"	Frontage International Limited, a company incorporated under the laws of Hong Kong and a wholly owned subsidiary of the Offeree as at the Latest Practicable Date, and will be wholly owned by Hongkong Tigermed after completion of the Separation Transaction;

"Frontage Labs"	Frontage Laboratories, Inc., a company incorporated under the laws of Pennsylvania, United States and a wholly-owned subsidiary of the Offeree as at the Latest Practicable Date, and will be indirectly wholly owned by CRL after completion of the Separation Transaction;
"Frontage Research"	Frontage Research, Inc., a corporation incorporated under the laws of Delaware, United States and a wholly-owned subsidiary of the Offeree as at the Latest Practicable Date, which will be owning the Non-Target Business outside of the PRC (excluding Acme Bioscience, Inc.) and be wholly owned by Frontage ACE after the completion of the Separation Transaction;
"H Shares"	the overseas listed foreign invested share(s) of nominal value of RMB1.00 each in the share capital of the Company which are listed on the Main Board of the Hong Kong Stock Exchange and subscribed for and traded in HK$;
"HK$"	Hong Kong dollars, the lawful currency of Hong Kong;
"Hong Kong"	the Hong Kong Special Administrative Region of the People's Republic of China;
"Hongkong Tigermed"	Hongkong Tigermed Co., Limited (香港泰格醫藥科技有限公司), a company incorporated under the laws of Hong Kong on September 14, 2011 and a wholly-owned subsidiary of the Company;
"Implementation Agreement"	has the meaning ascribed to it in the Announcement;
"Latest Practicable Date"	November 13, 2026, being the latest practicable date for the purpose of ascertaining certain information contained in this circular prior to its publication;
"Hong Kong Listing Rules"	the Rules Governing the Listing of Securities on the Stock Exchange;
"Non-Target Business"	the businesses and operations of the Offeree and its subsidiaries other than the Target Business, including those of the Non-Target Entities;
"Non-Target Entities"	Frontage Research, Frontage International Limited, and the subsidiaries listed on the Schedules II and III of the Transaction Agreement;

"Non-Target Liabilities"	all liabilities of the Offeree Group other than the Target Liabilities, in each case, regardless of (a) when or where such liabilities arose or arise (whether arising prior to, at or after the Effective Date), (b) where or against whom such liabilities are asserted or determined; (c) regardless of whether arising from or alleged to arise from negligence, gross negligence, recklessness, violation of law, fraud or misrepresentation by the Offeree or its subsidiaries, as the case may be, or any of their past or present respective directors, officers, employees, agents, or affiliates; and (d) which entity is named in any proceeding associated with any liability;
"Offeree" or "Frontage Holdings"	Frontage Holdings Corporation, an exempted company incorporated in the Cayman Islands with limited liability, the Offeree Shares of which are currently listed on the Main Board of the Stock Exchange (stock code: 1521);
"Offeree Share(s)"	the ordinary share(s) of US$0.00001 each in the issued share capital of Offeree;
"Offeror"	SanRex Limited, an exempted company incorporated in the Cayman Islands with limited liability, which is held as to 38.27%, 53.40%, 1.63%, 2.24%, 2.24% and 2.24% by CRL, Hongkong Tigermed, Dr. Li, The Linna Li GST Exempt Trust, The Wendy Li GST Exempt Trust and The Yue Monica Li GST Exempt Trust, respectively, as at the Latest Practicable Date, and will be wholly owned by CRL upon completion of the Separation Transaction;
"PRC"	the People's Republic of China;
"Pre-Conditions"	has the meaning ascribed to it in the Announcement;
"Proposal"	the proposal for the privatization of Offeree by the Offeror by way of the Scheme, the implementation of the Option Offer, the implementation of the Earnout Arrangement and the withdrawal of the listing of the Offeree Shares from the Stock Exchange, on the terms and subject to the conditions as described in the Announcement;
"Scheme"	the scheme of arrangement to be proposed under section 86 of the Companies Act (As Revised) of the Cayman Islands involving, among other things, the cancellation of all of the Scheme Shares and the maintenance of the issued share capital of Offeree at the amount immediately prior to the cancellation of the Scheme Shares;

"Scheme Record Date"	the record date to be announced for determining entitlements of the Scheme Shareholders under the Scheme;
"Scheme Shareholders"	the registered holders of the Scheme Shares;
"Scheme Shares"	the Offeree Shares in issue and such further Offeree Share(s) as may be issued on or prior to the Scheme Record Date;
"Securities Law"	the Securities Law of the People's Republic of China (《中華人民共和國證券法》);
"Separation Transaction"	the transaction to be effected and completed by the Offeree and its subsidiaries after completion of the Proposal, the key terms of which are further described in the section headed "D. The Transaction Agreement And The Separation Transaction – (I) Transaction Agreement" in the Announcement, including (i) certain transfers, distributions and contributions of the Target Assets, Target Liabilities, Non-Target Assets and Non-Target Liabilities among the Offeree and its subsidiaries (being the "**Asset Restructuring**"), (ii) adjustments to the Consortium Members' respective equity interests in the Offeror (including through transfer of Offeror Shares and cash payments among Hongkong Tigermed, CRL and Dr. Li and Dr. Li's Trusts and/or Frontage ACE, as elected by Dr. Li) to reflect the agreed valuation of the Target Business and the Non-Target Business (being the "**Adjustment of Ownership**"), and (iii) the distribution of the capital stock of certain subsidiaries of the Offeree, which will take up the Non-Target Assets and assume Non-Target Liabilities, to Hongkong Tigermed and Frontage ACE, in consideration for the redemption of the equity interests held by Hongkong Tigermed and Dr. Li and Dr. Li's Trusts in the Offeror (being the "**Equity Transfer**");
"Share(s)"	ordinary shares in the share capital of the Company, with a nominal value of RMB1.00 each, comprising A Shares and H Shares;
"Shareholder(s)"	the shareholder(s) of the Company, including the holders of A Share(s) and H Share(s);
"SZSE"	the Shenzhen Stock Exchange (深圳證券交易所);
"SZSE Listing Rules"	the Rules Governing the Listing of Shares on the SZSE;
"Stock Exchange"	The Stock Exchange of Hong Kong Limited;

"Target Business"	collectively, the bioanalysis and drug metabolism and pharmacokinetics (DMPK) business of the Offeree and its subsidiaries, including the laboratory science businesses and operations of Offeree and its subsidiaries located at the two sites in Exton, Pennsylvania listed on Schedule I of the Transaction Agreement, which includes the central labs and diagnostic services business, bioanalytical services business (both large and small molecule), biologics testing services business, biomarker services business and the drug metabolism and pharmacokinetics business, in each case of Offeree and its subsidiaries; provided that, for the avoidance of doubt, "Target Business" shall not include the chemistry, manufacturing and controls analytical business or the genomics business of Offeree and its subsidiaries;
"Target Liabilities"	any and all liabilities of Offeree and its subsidiaries to the extent arising from or related to the Target Assets, regardless of (a) when or where such liabilities arose or arise (whether arising prior to, at or after the Effective Date), (b) where or against whom such liabilities are asserted or determined, (c) regardless of whether arising from or alleged to arise from negligence, gross negligence, recklessness, violation of law, fraud or misrepresentation by Offeree or its subsidiaries, as the case may be, or any of their past or present respective directors, officers, employees, agents or affiliates and (d) which entity is named in any proceeding associated with any liability;
"Transaction Agreement"	has the meaning ascribed to it in the Announcement;
"Transactions"	the Proposal and the Separation Transaction;
"US$"	Dollars, the lawful currency of the US;
"%"	per cent.

HANGZHOU TIGERMED CONSULTING CO., LTD.
杭州泰格醫藥科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3347)

Executive Directors:
Dr. Ye Xiaoping
Ms. Cao Xiaochun
Mr. Wen Zengyu

Independent Non-executive Directors:
Mr. Yuan Huagang
Ms. Liu Yuwen
Mr. Siu, Paul Yu Hay

Employee Director:
Mr. Wu Hao

Registered Office:
Room 601-610, 6F
No. 508 Lujiatian Street
Puyan Sub-District
Binjiang District
Hangzhou
Zhejiang Province
the PRC

Principal Place of Business in Hong Kong:
40th Floor, Dah Sing Financial Centre
No. 248 Queen's Road East
Wanchai
Hong Kong

Hong Kong, November 17, 2026

To the Shareholders

Dear Sir or Madam,

(1) PRIVATIZATION AND SEPARATION TRANSACTION OF FRONTAGE HOLDINGS CORPORATION; AND (2) NOTICE OF 2026 FOURTH EXTRAORDINARY GENERAL MEETING

I. INTRODUCTION

References are made to the Announcement and the A Share Announcements. The purpose of this circular is (1) to provide further information in relation to the privatization and the asset disposal contemplated under the Proposal and the Separation Transaction; and (2) to provide you with all reasonable and necessary information to enable you to make an informed decision on whether to vote for or against the resolutions to be proposed at the EGM.

Unless otherwise defined in this circular, the terms and expressions used herein shall have the same meanings as those defined in the Announcement.

The following resolutions will be considered and, if thought fit, approved at the EGM:

ORDINARY RESOLUTIONS

1. To consider and approve the resolution on participating in the Proposal and asset disposal of Frontage Holdings, a subsidiary.

2. To consider and approve the resolution on requisitioning of the general meeting of Shareholders to authorize the Board to handle all matters related to the Proposal and the asset disposal.

Details of the Proposal and the asset disposal were set out in the Announcement and the A Share Announcements and are summarized below.

(I) Resolution on participating in the Proposal and the asset disposal of Frontage Holdings, a subsidiary

1. Overview of the Transactions

(1) The Transactions consist of two parts: the Proposal and the Separation Transaction. Hongkong Tigermed, a wholly-owned subsidiary of the Company, CRL, and Dr. Li, executive director and chairman of the board of directors of Frontage Holdings, together with Dr. Li's Trusts, jointly contributed to establishing the Offeror, and the Offeror serves as the acquisition vehicle to privatize Frontage Holdings, by way of the Scheme. Upon completion of the Proposal, Frontage Holdings will become a wholly-owned subsidiary of the Offeror.

As part of the Transactions, the parties will conduct the Separation Transaction in respect of Frontage Holdings, specifically including Asset Restructuring, Adjustment of Ownership and Equity Transfer. Following the consummation of the Asset Restructuring, (i) the Non-Target Assets and Non-Target Liabilities outside of the PRC (excluding Acme Bioscience, Inc.) will be held by Frontage Research or its subsidiaries, (ii) the Non-Target Assets and Non-Target Liabilities in the PRC and Acme Bioscience, Inc. will be held by Frontage International Limited or its subsidiaries, and (iii) the Target Assets and Target Liabilities will be held by Frontage Labs or its subsidiaries. Upon completion of the Transactions, the Offeror will retain only the Target Business, and the Target Business will ultimately be held by CRL; the Non-Target Business outside the PRC (excluding Acme Bioscience, Inc.) will be distributed to Frontage ACE by way of equity distribution; and the Non-Target Business in the PRC will be retained by Hongkong Tigermed by way of equity distribution.

Frontage Labs is an overseas subsidiary of Frontage Holdings which was acquired by the Company in 2014 through cash investment via its wholly-owned subsidiary Hongkong Tigermed. Frontage Holdings has been listed on the Hong Kong Stock Exchange since May 2019 (stock code: 01521.HK). Its headquarters and R&D and clinical trial centers are all located in the United States, and its business headquarters in the PRC is located in Shanghai.

Based on commercial considerations and market capitalization of the Offeree, the consideration attributable to the Target Business, the Non-Target Business, and the Non-Target Business are US$470 million, US$84.4 million, and US$205.5 million, respectively. Customary adjustments will be made in accordance with the terms of the Transaction Agreement, and initial estimated cash payments will be made at closing. Such payments will subsequently be customarily "trued up" through delivery of closing statements to be prepared within 120 days after the Closing.

(2) As at the Latest Practicable Date, the Company held an aggregate of 64.48% of the shares of Frontage Holdings; upon completion of the Transactions, the Company will no longer hold any shares of Frontage Holdings and will retain only the Non-Target Business in the PRC.

Based on the relevant audit report provided by Frontage Holdings, the key audited financial data of Frontage Holdings for the year ended December 31, 2025 and the six months ended June 30, 2026 are set forth below:

Unit: USD'000

Items	**As at December 31, 2025/for the year ended December 31, 2025** *(Audited)*	**As at June 30, 2026/for the six months ended June 30, 2026** *(Audited)*
Total Assets	541,024	580,474
Total Liabilities	192,978	224,248
Net Assets	348,046	356,226
Operating Revenue	256,691	148,190
Net Profit	6,762	6,788

2. Purpose of the Transactions and Impact on the Company

(1) The Proposal, together with the subsequent Separation Transaction, presents an opportunity for the Company to divest its overseas laboratory services business which is of a different nature to the Company's core clinical CRO business. There is a multitude of differences between clinical CRO business and laboratory services business. For example, the clinical CRO business of the Company focuses on clinical operations, site management, regulatory affairs, data management and biometrics etc. and requires expertise in project management, medicine, local and global regulations and statistics etc., while the laboratory services business of the Offeree relies heavily on laboratory facilities and focuses on chemistry, biology, CMC, pre-clinical research (DMPK, safety and toxicology) and laboratory testing (bioanalytical and biologics, and central laboratory) etc. and requires expertise in chemistry and manufacturing etc.

Divesting the overseas laboratory services business allows the Company to have a substantially smaller scale of laboratory services business and allows the Company to better focus on its core clinical CRO business for better strategic planning, capital allocation, and operational improvement decisions.

(2) The growth opportunity, customer focus and expansion strategy of Frontage Holdings are different from the Chinese market where the Company is headquartered and maintains its leadership position. The majority of the business operations and assets of the Offeree are carried on or situated outside China, therefore involving operating cost and overseas operation and management requirements that are separate from the Company's core clinical CRO business. The Proposal, together with the subsequent Separation Transaction, will allow the Company to optimize its geographical focus by divesting its overseas laboratory business. This allows the Company to better focus on China, the second largest biopharmaceutical market globally. In addition, by consolidating the business operations of the remaining laboratory services in China, the Company can centralize the management and streamline decision-making process, thereby improving cost and decision-making efficiency and operational focus, which is in line with the long-term strategic development goal of the Company.

(3) The Company expects to receive, at the completion of the Proposal, cash consideration of HK$535,667,400 corresponding to the 11.09% shares of Frontage Holdings directly held by the Company and to be canceled (equivalent to approximately RMB461.2 million, calculated at the RMB-to-HK$ exchange rate of 1:1.1615 as of November 9, 2026) (before deducting taxes and related expenses).

Upon completion of the Proposal, Hongkong Tigermed, a wholly-owned subsidiary of the Company, will divest the Target Business and the Non-Target Business outside the PRC (excluding Acme Bioscience, Inc.) through the Adjustment of Ownership and the Equity Transfer as part of the Separation Transaction, and Hongkong Tigermed will obtain further cash consideration from the Adjustment of Ownership. The specific amount of cash consideration to be received by Hongkong Tigermed will need to be ultimately determined in light of the adjustments made in accordance with the Transaction Agreement, as summarized in the Announcement.

In addition to the above consideration, the Transactions include the Earnout Arrangement. If the Target Business achieves the performance targets for revenue and adjusted EBITDA margin for the fiscal years 2026 and 2027, the Company as Scheme Shareholder on the Scheme Record Date and Hongkong Tigermed, will receive the corresponding payment under the Earnout Arrangement.

Upon completion of the Transactions, the Company will account for the investment income in accordance with the relevant provisions of the Accounting Standards for Business Enterprises established by the Ministry of Finance of the PRC and other applicable regulations, and the final figures shall be subject to further determination and audit and will be disclosed in the Company's annual report.

(4) The pricing of the Transactions is fair, the terms are fair and reasonable, and the Transactions are conducted on normal commercial terms or better, which are in the interests of the Company and all its Shareholders and do not prejudice the lawful rights and interests of the Company and all its Shareholders, especially the minority Shareholders. They will not have an adverse impact on the Company's normal production and operations, nor will they result in any horizontal competition.

3. Approval Procedures for the Transactions

The Transactions do not constitute a related-party transaction as stipulated in the SZSE Listing Rules, nor do they constitute a major asset restructuring as stipulated in the Administrative Measures for Major Asset Restructurings of Listed Companies.

However, Dr. Li, as executive director and chairman of the board of Frontage Holdings and CEO of Frontage Holdings, is a connected person of the Company at the subsidiary level pursuant to the Hong Kong Listing Rules, the Transactions constitute connected transactions under the Hong Kong Listing Rules. For the reasons set out in the section headed "Hong Kong Listing Rules Implications" of the Announcement, the Transactions are exempt from the circular, independent financial advice, and shareholders' approval requirements under Rule 14A.101 of the Hong Kong Listing Rules.

Pursuant to Rule 7.1.3 of the SZSE Listing Rules, because the profit expected to be generated by the Transactions will account for more than 50% of the Company's audited net profit for the most recent accounting year, and the absolute amount exceeds RMB5 million, the Transactions are required to be submitted to the EGM for consideration.

The Transactions are subject to the fulfillment of Pre-Conditions and Conditions and may or may not proceed. Shareholders and potential investors of the Company, the Offeror or the Offeree are advised to exercise caution when dealing in the securities of the Company, the Offeror or the Offeree.

(II) Resolution on the requisitioning of the general meeting of Shareholders to authorize the Board to handle all matters related to the Proposal and the asset disposal

To ensure the smooth implementation of the Transactions, the Board, in accordance with the relevant provisions of the Company Law, the Securities Law, and other laws and regulations, as well as the Articles of Association, proposes that the EGM authorize the Board, and authorize the Board to sub-delegate to the chairman of the Board and his authorized persons, to fully handle matters relating to the Transactions, including but not limited to:

1. Amending and implementing the specific matters of the Transactions, in accordance with the provisions of laws, regulations and relevant regulatory documents, including but not limited to adjusting the prices of the relevant target assets and the specific contents of the transaction documents, and other matters as appropriate to the particular circumstances;

2. Executing agreements in relation to the Transactions, including the Consortium Agreement, the Transaction Agreement, and the Implementation Agreement, as well as supplemental agreements, letters of commitment, letters of confirmation and other legal documents; making reasonable amendments and improvements to the relevant documents;

3. Handling closing matters in relation to the Transactions;

4. Obtaining and securing all approvals and consents from relevant governmental authorities and/or regulatory agencies regarding the Transactions (if applicable), in accordance with the provisions of applicable laws (including but not limited to the Company Law, the Securities Law, the Hong Kong Listing Rules, and the SZSE Listing Rules);

5. Handling approvals, registrations, filings, consents, reports, and other procedures with the relevant governmental authorities or regulatory agencies relating to the Transactions (if applicable);

6. Handling other matters in relation to the Transactions within the scope permitted by laws, regulations, relevant regulatory documents, and the Articles of Association.

The above authorization shall be valid from the date of consideration and approval by the EGM to the date of completion of the above authorization matters.

II. CLOSURE OF REGISTER OF MEMBERS

In order to ascertain the entitlement to attend and vote at the EGM, the register of members of the Company will be closed from Tuesday, December 1, 2026 to Friday, December 4, 2026, both days inclusive, during which no transfer of Shares will be effected. The record date of the entitlement to attend and vote at the EGM will be Friday, December 4, 2026. In order to determine whether Shareholders are entitled to attend and vote at the EGM, all transfer documents accompanied by the relevant share certificates must be lodged with the Company's H Share Registrar Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong for registration no later than 4:30 p.m. on Monday, November 30, 2026.

III. EXTRAORDINARY GENERAL MEETING

The EGM will be held at 10:00 a.m. on Friday, December 4, 2026 at the Conference Room, 6/F, No. 508 Lujiatian Street, Puyan Sub-District, Binjiang District, Hangzhou, the PRC. The form of proxy for use at the EGM was published on the website of the Stock Exchange (www.hkexnews.hk) and the Company (www.tigermedgrp.com) on Tuesday, November 17, 2026.

As disclosed in the Announcement, each of Dr. Ye Xiaoping and Ms. Cao Xiaochun (each being a Director and Shareholder of the Company, and are interested in an aggregate of 228,553,715 A Shares as at the Latest Practicable Date, representing approximately 26.73% of the total issued Shares) has given an irrevocable undertaking, pursuant to which they will vote in favor of the two resolutions at the EGM.

None of the Shareholders has any material interest in any of the resolutions to be proposed at the EGM and is required to abstain from voting at the EGM.

No Director has a material interest in any of the resolutions to be proposed at the EGM.

IV. RECOMMENDATION

The Directors (including the independent non-executive Directors) believe that the resolutions set out in this circular are in the best interests of the Company and the Shareholders as a whole. Accordingly, the Directors recommend the Shareholders to vote in favor of the resolutions.

V. RESPONSIBILITY STATEMENT

This circular, for which the Board collectively and individually accepts full responsibility, includes particulars given in compliance with the Hong Kong Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this circular is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this circular misleading.

VI. FURTHER INFORMATION

In the event of any discrepancy between the English translation and the Chinese version of this circular, the Chinese version shall prevail.

Yours faithfully,
By Order of the Board
Hangzhou Tigermed Consulting Co., Ltd.
Ye Xiaoping
Chairman

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this notice.

This announcement appears for information purposes only and is not intended to and does not constitute, or form part of, an invitation or offer to acquire, purchase or subscribe for any securities of the Company, the Offeror or the Offeree nor is it a solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance or transfer of securities of the Company, the Offeror or the Offeree in any jurisdiction in contravention of applicable law or regulation.

This announcement is not for release, publication or distribution, in whole or in part, in, into or from any jurisdiction where to do so would constitute a violation of the Applicable Laws of such jurisdiction.

HANGZHOU TIGERMED CONSULTING CO., LTD.

杭州泰格醫藥科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3347)

NOTICE OF THE 2026 FOURTH EXTRAORDINARY GENERAL MEETING

NOTICE IS HEREBY GIVEN that the extraordinary general meeting (the "**EGM**") of Hangzhou Tigermed Consulting Co., Ltd. (the "**Company**") will be held at 10:00 a.m. on Friday, December 4, 2026 at the Conference Room, 6/F, No. 508 Lujiatian Street, Puyan Sub-District, Binjiang District, Hangzhou, the PRC, or any adjournment thereof, for the purpose of considering and, if thought fit, approving the following resolutions. Unless the context otherwise requires, the terms and expressions used herein shall have the same meanings as those defined in the circular dated November 17, 2026 of the Company (the "**Circular**") and the Announcement (as defined in the Circular).

ORDINARY RESOLUTIONS

1. To consider and approve the resolution on participating in the Proposal and asset disposal of Frontage Holdings, a subsidiary.

2. To consider and approve the resolution on requisitioning of the general meeting of Shareholders to authorize the Board to handle all matters related to the Proposal and the asset disposal.

By order of the Board
Hangzhou Tigermed Consulting Co., Ltd.
Ye Xiaoping
Chairman

Hong Kong, November 17, 2026

As at the date of this notice, the executive Directors are Dr. Ye Xiaoping, Ms. Cao Xiaochun and Mr. Wen Zengyu; the employee Director is Mr. Wu Hao; the independent non-executive Directors are Mr. Yuan Huagang, Ms. Liu Yuwen and Mr. Siu, Paul Yu Hay.

Notes:

1. The voting at the EGM will be conducted by way of poll.

2. Holders of A Shares and H Shares will vote as one class of Shareholders. The Company's register of members for the H Shares will be closed from Tuesday, December 1, 2026 to Friday, December 4, 2026, both days inclusive, during which no transfer of H Shares will be effected. Holders of H Shares of the Company whose names appear on the Company's register of members of H Shares on Friday, December 4, 2026 are entitled to attend the EGM. In order to be entitled to attend at the EGM, holders of H Shares whose transfers have not been registered must deposit the transfer documents together with the relevant share certificates at the H Share Registrar of the Company, Tricor Investor Services Limited no later than 4:30 p.m. on Monday, November 30, 2026. The address of Tricor Investor Services Limited is 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong.

3. Each Shareholder entitled to attend and vote at the EGM may appoint one or more proxies to attend and vote on his or her behalf. A proxy needs not to be a Shareholder. Each Shareholder who wishes to appoint one or more proxies should first review the Circular.

4. An ordinary resolution shall be passed by votes representing the majority of the voting rights held by the Shareholders (including proxies thereof) attending the EGM.

5. The form of proxy must be signed by the Shareholder or his/her attorney duly authorized in writing. If the Shareholder is a corporation, the instrument must be either under its common seal or signed by the director or his/her attorney duly authorized. If the instrument is signed by an attorney of the Shareholder, the power of attorney authorizing that attorney to sign or other authorization document must be notarized.

6. In order to be valid, the form of proxy of holders of H Shares together with the power of attorney or other authorization documents (if any) signed by the authorized person or notarially certified power of attorney must be deposited at Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong not less than 24 hours before the time appointed for holding the EGM or any adjournment thereof (as the case may be). Completion and return of a form of proxy will not preclude a Shareholder from attending and voting in person at the EGM if he/she so wishes.

7. The EGM is expected to last for no more than half a day. Shareholders (or their proxies) attending the EGM are responsible for their own transportation and accommodation expenses. Shareholders (or their proxies) attending the EGM must produce their identity documents.

8. All times refer to Hong Kong local time unless otherwise stated.